2019
Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era
Kadatz M, Gill JS, Gill J, Formica RN, Klarenbach S. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era. Journal Of The American Society Of Nephrology 2019, 31: 218-228. PMID: 31704739, PMCID: PMC6934999, DOI: 10.1681/asn.2019070646.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsQuality-adjusted life yearsTransplant recipientsTransplant survivalDrug coverageMedicare coverageTransplant failureImmunosuppressant drugsAdditional quality-adjusted life yearCohort of MedicareMultivariable survival analysisIncremental cost-utility ratioBetter patient outcomesCost-utility ratioImmunosuppressant medicationsTransplant functionImmunosuppressive drugsPatient outcomesMedicare payersSurvival analysisLife yearsIncremental costRecipientsSurvivalDrugs
2013
Written Informed Consent for Living Kidney Donors: Practices and Compliance With CMS and OPTN Requirements
Thiessen C, Kim YA, Formica R, Bia M, Kulkarni S. Written Informed Consent for Living Kidney Donors: Practices and Compliance With CMS and OPTN Requirements. American Journal Of Transplantation 2013, 13: 2713-2721. PMID: 24020884, DOI: 10.1111/ajt.12406.Peer-Reviewed Original ResearchConceptsConsent formKidney donorsKidney donor evaluationLiving Kidney DonorsKidney transplantRoutine followTransplant centersDonor evaluationUS CentersOPTN policyOrgan procurementHealth problemsInformed consentInformed consent practicesPrior yearSurgeryDonor consentConsentConsent practicesDonorsComplicationsTransplantComplianceFollowYears